Introduction
The 2009 Pan Pacific Lymphoma Conference was held June 22-26, 2009 bringing together hundreds of lymphoma experts from around the world to share knowledge and patient care experiences. Chairs Julie Vose and James Armitage of the University of Nebraska Medical Center hosted 5 days of thought-provoking lectures, debates, and case presentations designed with the ultimate goal of improving patient care outcomes.
Featured Content
• Maintenance Therapy in Indolent NHL
• Optimizing Regimens in Aggressive NHL
• Optimizing Regimens in Hodgkin’s Lymphoma
• Development of Novel Agents for NHL
Editors
John P. Leonard, MD, bio | Michael E. Williams, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: August 12, 2009 | Expiration date: August 11, 2010
Statement of Need
For the first time in years, several advances have been made in the management of lymphoid malignancies, including improved survival as a result of the integration of monoclonal antibodies and the introduction of novel therapies. Despite these improvements, several issues remain. Where do the available therapies for lymphoid malignancies fit within the context of currently accepted treatment standards? How should novel therapies for lymphoid malignancies be integrated? What about sequencing? Can novel therapies be used in combination regimens? What are the most rational combination regimens for lymphoid malignancies? What side effects can be expected from these novel therapy combinations? US-based practitioners, charged with the care of patients with lymphoid malignancies, must have in-depth knowledge of current preclinical and clinical data in order to make the most appropriate treatment-related decisions for his/her patients with a lymphoid malignancy and must understand the placement of said data in the context of the US patient.
Target Audience
The target audience for the program includes hematologists, hematologist-oncologists, and allied healthcare professionals caring for patients with lymphoid malignancies.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Describe the importance of diagnostic and pathologic evaluation of lymphoid malignancies
- Understand the rationale for the development and integration of treatment strategies in lymphoid malignancies
- Examine clinical trial results of treatment regimens, both containing novel agents and combinations, in patients with lymphoid malignancies
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
|
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UPN 199-000-09-033-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity.
During the period August 12, 2009 through August 11, 2010, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF CONFLICT OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Educational Concepts Group, LLC (ECG) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE
Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net |
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
John P. Leonard, MD
Consultant/Advisor
Biogen IDEC, Biotest, Celgene Corporation, Enzon, Genentech, GlaxoSmithKline, Gloucester Pharmaceuticals, Immunomedics, Inc.,
Johnson & Johnson, Millennium Pharmaceuticals, Inc., Novartis
Michael E. Williams, MD
Grants/Research Support
Biogen IDEC, Celgene Corporation, Cephalon, Genentech BioOncology, Millennium Pharmaceuticals, Inc.
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Celgene Corporation and Genentech BioOncology and Biogen Idec.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
